The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. [electronic resource]
Producer: 19991217Description: 2310-7 p. digitalISSN:- 0315-162X
- Antibodies -- adverse effects
- Arthritis, Rheumatoid -- immunology
- Autoantibodies -- analysis
- CD4 Antigens -- blood
- Collagen -- urine
- Collagen Type I
- Female
- Humans
- Interleukin-6 -- blood
- Leukocytes, Mononuclear -- physiology
- Lymphocyte Activation
- Male
- Matrix Metalloproteinase 3 -- blood
- Middle Aged
- Peptides -- urine
- Phenotype
- Receptors, Interleukin-2 -- blood
- Recombinant Proteins -- immunology
- T-Lymphocytes -- drug effects
- Tumor Necrosis Factor-alpha -- immunology
No physical items for this record
Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.